Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21373523 | 0.81 | ALDH1A1 (0.52) | BRD9ALDH1A1MAPTCMA1BRD7 | |
| SCHEMBL21373558 | 0.80 | BRD9 (0.40) | BRD9ALDH1A1MAPTCMA1BRD7 | |
| SCHEMBL21373529 | 0.76 | BRD9 (0.45) | BRD9ALDH1A1MAPTCMA1BRD7 | |
| SCHEMBL20379088 | 0.75 | TSHR (0.50) | ALDH1A1MAPTCMA1PKMTSHR | |
| SCHEMBL21373652 | 0.75 | BRD9 (0.44) | BRD9ALDH1A1MAPTCMA1BRD7 | |
| SCHEMBL21373566 | 0.73 | POLB (0.45) | BRD9ALDH1A1MAPTCMA1AR | |
| SCHEMBL21373584 | 0.73 | KDM4E (0.45) | BRD9ALDH1A1MAPTCMA1BRD7 | |
| SCHEMBL21373513 | 0.73 | ALDH1A1 (0.45) | BRD9ALDH1A1MAPTCMA1BRD7 | |
| SCHEMBL21373636 | 0.72 | CMA1 (0.43) | BRD9ALDH1A1MAPTCMA1PKM | |
| SCHEMBL21373641 | 0.70 | PTGS2 (0.41) | BRD9ALDH1A1MAPTCMA1BRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768673-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2021-01-27 | — | — | EP | claimed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | claimed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | claimed |
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | disclosed |
| CN-116462666-A | Cytoprotective compounds and uses thereof | 瑞士苏黎世联邦理工学院 | 2023-07-21 | — | — | CN | disclosed |
| US-11628159-B2 | Cell-protective compounds and their use | ETH ZURICH (CH) | 2023-04-18 | — | — | US | disclosed |
| EP-3768673-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2021-01-21 | — | — | US | disclosed |
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH Zürich (CH) | 2019-11-14 | — | — | US | disclosed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | SRPK2, SRSF2, SRPK1 | BRD9 3804/4885ALDH1A1 3877/4885MAPT 4699/4885 |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | PPT1, SPTLC1, LPCAT1 | BRD9 2162/4885ALDH1A1 712/4885MAPT 91/4885 |
| US-11628159-B2 | Cell-protective compounds and their use | SRPK2, SRSF2, SRPK1 | BRD9 3804/4885ALDH1A1 3877/4885MAPT 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.